Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

KIMMTRAK (tebentafusp) 200 micrograms/ mL concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
tebentafusp
Company:  
Immunocore Limited See contact details
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

▼KIMMTRAK® (tebentafusp) - Important information for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

Important information about ▼KIMMTRAK® (tebentafusp) Information to assist healthcare professionals: • Description of Cytokine Release Syndrome (CRS) and Acute Skin Reactions in patients treated with tebentafusp, including severity, frequency, time to onset, treatment, and resolution. • How to manage CRS and acute skin reactions based on severity grade including information when corticosteroid premedication is recommended. • Monitoring requirements for patients during the first three infusions and for subsequent infusions. • How to minimise the risk of hypotension associated with CRS. • Description of the ECG schedule and management requirements based on the ECG results. • Recommendation to carefully monitor patients with cardiac disease, QT prolongation and risk factors for cardiac failure. • Information on the importance of informing patients of the risk of CRS and Acute Skin Reactions, and the need to immediately contact their doctor or nurse if they develop any symptoms of CRS or Acute Skin

{pdf_link}

▼KIMMTRAK ® (tebentafusp) – Patient Guide

The information in this brochure is for patients who are being given tebentafusp. It is administered by your doctor. Your doctor will also talk with you about this brochure and important information for you like the benefits and the risks of tebentafusp therapy and what to expect regarding your monitoring schedule.

{pdf_link}

▼KIMMTRAK ® (tebentafusp) – Patient Guide LARGER PRINT

The information in this brochure is for patients who are being given tebentafusp. It is administered by your doctor. Your doctor will also talk with you about this brochure and important information for you like the benefits and the risks of tebentafusp therapy and what to expect regarding your monitoring schedule.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Immunocore Limited
Company image
Address
92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK
WWW
https://www.immunocore.com/
Telephone
+44 (0)1235 438600
Medical Information Direct Line
+44 (0) 2076645100
Medical Information e-mail
[email protected]